Our Pricing

Wegovy Injection Prescription Weight Loss UK: Clinical Guide

Searching for wegovy injection prescription weight loss UK options? Wegovy (semaglutide) is a once-weekly injectable treatment licensed by the MHRA for chronic weight management in adults with obesity or weight-related health conditions. At Cured Pharmacy, our UK-registered clinical team provides free online consultations, transparent pricing from £79.00, and discreet next-day delivery of genuine UK-licensed Wegovy pens.

How Wegovy Injection Works for Prescription Weight Loss

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics a natural hormone your body produces after eating [1]. By activating GLP-1 receptors in the brain, pancreas, and digestive system, semaglutide reduces appetite, slows gastric emptying, and improves blood sugar regulation — creating the physiological conditions for sustainable weight loss.

In the landmark STEP 1 clinical trial involving 1,961 adults with obesity, participants using Wegovy achieved an average 14.9% body weight reduction over 68 weeks, compared to 2.4% with placebo [1]. Importantly, 86.4% of Wegovy users lost at least 5% of their body weight, meeting the clinical threshold for meaningful health improvements.

Wegovy is administered as a subcutaneous injection once weekly, typically in the abdomen, thigh, or upper arm. The treatment follows a dose-escalation schedule, starting at 0.25 mg weekly and gradually increasing to the maintenance dose of 2.4 mg over 16-20 weeks [2]. This gradual titration minimises gastrointestinal side effects while allowing your body to adapt to the medication.

Who Can Use Wegovy Injection in the UK

Wegovy is licensed in the UK for adults with a body mass index (BMI) of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or obstructive sleep apnoea [2]. NICE guidance recommends considering GLP-1 receptor agonists as part of a comprehensive weight management programme including dietary modification and increased physical activity.

Before prescribing Wegovy, UK clinicians assess your complete medical history, current medications, and suitability for GLP-1 therapy. Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [2]. Pregnant or breastfeeding women should not use Wegovy, and the medication should be discontinued at least two months before planned conception.

At Cured Pharmacy, our UK-registered prescribers (working under superintendent pharmacist Tarun Kumar, GPhC 2233073) conduct thorough online consultations to determine whether Wegovy is clinically appropriate for you. The assessment takes under three minutes and evaluates your weight history, previous weight loss attempts, current health conditions, and treatment goals.

Medical Conditions That May Affect Wegovy Suitability

Patients with a history of pancreatitis, severe gastrointestinal disease, diabetic retinopathy, or renal impairment require careful clinical evaluation before starting Wegovy. Your prescriber will review your complete medication list to identify potential drug interactions, particularly with insulin or sulfonylureas, which may require dose adjustments to prevent hypoglycaemia [3].

Wegovy Dosing Schedule and Administration

Wegovy follows a structured dose-escalation protocol designed to optimise tolerability and clinical outcomes. The standard titration schedule begins at 0.25 mg once weekly for four weeks, then increases to 0.5 mg for four weeks, 1 mg for four weeks, 1.7 mg for four weeks, and finally reaches the maintenance dose of 2.4 mg weekly [2].

Each Wegovy pen is pre-filled and single-use, eliminating the need for manual dosing calculations or needle assembly. You inject subcutaneously into the abdomen, thigh, or upper arm, rotating injection sites weekly to reduce lipodystrophy risk. The medication can be administered at any time of day, with or without meals, though maintaining a consistent weekly schedule optimises therapeutic consistency.

If you miss a dose and the next scheduled dose is more than two days away, administer the missed dose as soon as possible. If fewer than two days remain, skip the missed dose and resume your regular schedule [2]. Never double doses to compensate for missed injections, as this increases the risk of gastrointestinal adverse effects.

Storage and Handling Requirements

Unopened Wegovy pens must be refrigerated at 2°C to 8°C and protected from light. Once in use, pens may be stored at room temperature (up to 30°C) for up to 28 days. Never freeze Wegovy, and discard any pens that have been frozen. Always check the expiration date before use and dispose of used pens in a sharps container according to local regulations.

Clinical Evidence: STEP Trial Programme Results

The STEP (Semaglutide Treatment Effect in People with obesity) clinical trial programme represents the most comprehensive evaluation of semaglutide 2.4 mg for weight management, encompassing over 4,500 participants across five international trials [1][4]. These randomised, double-blind, placebo-controlled studies established both the efficacy and safety profile that supported MHRA licensing.

STEP 1, the pivotal trial, demonstrated that 68 weeks of Wegovy treatment produced a mean body weight reduction of 14.9%, with one-third of participants achieving at least 20% weight loss [1]. Beyond the scale, participants experienced clinically meaningful improvements in cardiometabolic risk factors: systolic blood pressure decreased by 6.2 mmHg, waist circumference reduced by 13.5 cm, and HbA1c levels improved significantly in those with prediabetes.

The STEP 4 trial examined weight maintenance after initial weight loss, finding that participants who continued Wegovy maintained their weight loss, whilst those switched to placebo regained 6.9% of their body weight over 48 weeks [4]. This evidence underscores that Wegovy is a long-term treatment requiring ongoing use to sustain clinical benefits, similar to other chronic disease medications.

Common Side Effects and How to Manage Them

The most frequently reported side effects of Wegovy are gastrointestinal: nausea (44% of participants), diarrhoea (30%), vomiting (24%), and constipation (24%) in clinical trials [1]. These effects are typically mild to moderate in severity, occur predominantly during dose escalation, and diminish over time as your body adapts to the medication.

To minimise gastrointestinal symptoms, eat smaller, more frequent meals rather than large portions, avoid high-fat and spicy foods, and stay well-hydrated throughout the day. Taking Wegovy with food does not affect absorption, so you may time your injection to coincide with lighter meal periods if nausea is problematic. If symptoms persist or worsen, consult your prescriber, who may slow the dose escalation schedule.

Serious adverse events are rare but include pancreatitis (characterised by severe abdominal pain radiating to the back), gallbladder disease, acute kidney injury, and hypoglycaemia in patients taking concomitant insulin or sulfonylureas [2][3]. Seek immediate medical attention if you experience persistent severe abdominal pain, visual changes, or signs of allergic reaction such as facial swelling or difficulty breathing.

Long-Term Safety Considerations

Clinical trials up to 68 weeks have established Wegovy's safety profile, though long-term data beyond two years remains limited. Regular monitoring by your healthcare provider ensures early detection of potential complications. Women of childbearing potential should use effective contraception during treatment, as weight loss itself may increase fertility and Wegovy's effects on pregnancy are not fully characterised [2].

Getting Wegovy Through Cured Pharmacy

Accessing Wegovy through Cured Pharmacy combines clinical rigour with convenience and transparency. Our process begins with a free online consultation that takes under three minutes to complete, during which you provide your medical history, current medications, weight management goals, and previous treatment attempts. This information is reviewed by a UK-registered prescriber who determines whether Wegovy is clinically appropriate for you.

If approved, your prescription is dispensed by our GPhC-registered pharmacy (registration number 9012511) and dispatched in 100% discreet packaging for next-day delivery across the UK. We supply only genuine UK-licensed Wegovy manufactured by Novo Nordisk, never grey-market or imported alternatives. Our transparent pricing model shows exact costs before you begin the consultation — no hidden fees or surprise charges.

Ongoing clinical support is included with your treatment. You can contact our pharmacy team on (+44) 116 4646009 during business hours for dosing questions, side effect management, or prescription renewals. We recommend scheduling follow-up consultations every 12 weeks to assess treatment response, adjust doses if needed, and ensure Wegovy remains the optimal choice for your weight management journey.

Why Choose Cured Pharmacy for Wegovy

Our lowest price guarantee ensures you receive competitive UK pricing without compromising on clinical quality or regulatory compliance. Unlike some providers, we display pricing upfront before consultation, allowing you to make informed decisions. Our UK-registered clinical team, led by superintendent pharmacist Tarun Kumar (GPhC 2233073), prioritises patient safety and evidence-based prescribing in every consultation.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Novo Nordisk. (2023). Wegovy 2.4 mg Solution for Injection in Pre-filled Pen: Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/13799
3. Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., & Lingvay, I. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0
4. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., Rudofsky, G., Tadayon, S., Wadden, T. A., & Dicker, D. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary and are not guaranteed.